Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 12Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Prostatic Neoplasms 4Solid Tumor 3Neoplasm Metastasis 3Melanoma 3Recurrence 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Choledocholithiasis 2Carcinoma 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Terminal Cancer 1Synovitis, Pigmented Villonodular 1Stomach Neoplasms 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Skin Neoplasms 1Respiratory Aspiration 1Respiration Disorders 1Rectal Neoplasms 1Rare Diseases 1Prostate Cancer Patients 1

Interventions

carbon-11 acetate 1Warfarin 1Omeprazole 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostate Cancer Patients × Midazolam × Clear all
NCT04676035 2023-02-09

The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
18 enrolled
Genitourinary

Prostate Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡